Journal of Neurology & Neurophysiology

Magnesium is necessary for the presynaptic release of acetylcholine from nerve endings and may produce effects similar to calciumentry- blocking drugs [1]. With the discovery of the N-methyl- D-aspartate (NMDA) receptor and its links to nociceptive pain transmission and central sensitization, there has been renewed interest in utilizing noncompetitive NMDA receptor antagonists, as potential antihyperalgesic agents. The magnesium ion was the first agent discovered to be an NMDA channel blocker. At high doses, perioperative intravenous magnesium sulfate has been reported to reduce postoperative morphine consumption. Therefore, when magnesium sulfate is co-administered with propofol, it potentiates the anesthetic effect and NMDA antagonism of propofol [2].

Magnesium sulfate has vasodilator and hypotensive effect and therefore potentiates the hypotensive effect of propofol [3]. Magnesium sulfate also, has demonstrated a variety of neuroprotective actions in the central nervous system after induction of experimental ischemia and in clinical studies [4]. The CNS depressant effect of anesthetic agents may be potentiated when they are used concurrently with magnesium sulfate [5].

Previous studies have reported that preoperative administration of magnesium sulfate reduces intra- and post-operative analgesic requirements in patients undergoing knee surgery or abdominal hysterectomy [5]. However, most of those studies evaluated the analgesic and anesthetic requirements depending on clinical parameters mainly such as hemodynamics and pain score.

Study groups

This work had been carried out during the period from January 2009 to June 2011 after approval of the ethical committee (Ethical Committee N^o KKUH 106) of King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia on 10 December 2008. Written informed consents were obtained from all patients prior to entry into the study. The study included sixty adult male and female patients, ASA physical status I and II, with average weight and height, and undergoing neurosurgical procedures. Patients with significant organ dysfunctions (e.g. cardiac, respiratory, renal, or liver disorders), morbid obese or those on treatments with calcium channel blockers were excluded from the study.

All patients received oral lorazepam (1-2 mg) and ranitidine (150 mg) as a premedication (1-2 hours) preoperatively. Before induction of anesthesia, patients in group (I) received the unknown solution (A), while patients in group (II) received the unknown solution (B) in a double blind fashion. The solutions were prepared in the pharmacy and the anesthetist was blinded to the grouping design. Patient in group (I) received magnesium sulfate (20 mg/kg) as bolus dose over 5 minutes before induction of anesthesia, followed by (0.1 ml/kg/h) of 10% solution as continuous infusion. While patients in group (II) received saline with the same bolus and infusion rates, during the entire anesthesia period. Postoperative pain management was conducted by the acute pain team (APS) who was also blinded to the group assignment.

Anesthetic technique

As the patient was received in theatre, all the standard monitors were applied including HR, arterial blood pressure, ECG, Spo₂, Etco₂ and temperature, in addition to neuromuscular monitoring ‘TOF’. ‘BIS’ electrodes (BIS QUATRO - BX13366, Aspect Medical Systems, Inc. USA) were applied and connected to the monitoring system that was attached to the anesthesia machine (Zeus, Drager Medical & Co.KG, 23542 Lubeck, Germany). After induction of anesthesia, arterial line was inserted for continuous monitoring of the blood pressure and frequent blood gas analysis.

Induction of anesthesia carried out with intravenous fentanyl (2 μg/kg), followed by propofol (1.5-2 mg/kg). Intubation was carried using rocuronium bromide in a dose of (0.6 mg/kg). Maintenance of anesthesia was carried by continuous infusion of propofol (6-8 mg/kg/h) and was titrated to maintain the ‘BIS’ value within the range between (40-50) and fentanyl (1-2 μg/kg/h) to maintain the hemodynamic parameters within (20%) of the base line preoperative values. Muscle relaxation was monitored by ‘TOF’ every ten minutes, and when the ‘TOF’ stimulations were more than two responses, additional boluses of rocuronium (0.2 mg/kg) were administered. Lungs were mechanically ventilated to maintain normocapnia.

Baseline intravenous infusion rate of Lactated Ringer’s solution was set at 6 ml/kg/h in both groups. Additional solutions were infused if required. Infusion solutions were stopped as the surgeon started skin repair. At the end of the surgery, all anesthetics and solutions were withdrawn. The residual effect of rocuronium was reversed with neostigmine in a dose of (0.05 mg/kg) and glycopyrolate (4 mg). Then the patient was extubated and transferred to either post anesthesia care unit ‘PACU’ or high dependency care unit ‘HDU’ for routine follow up. Every patient was observed continuously after the termination of anesthesia and times of events or any adverse events were recorded.

Pain was assessed by the VAS (0-100 mm) at immediate postoperative period till 48 h postoperative. Post operative pain relief was achieved by I.V morphine using patient controlled analgesia “PCA II Syringe Pump Product of Baxter Healthcare Corporation”. The PCA machine was containing a dose of 50 mg morphine in a total volume of 50 ml saline (1 mg/mL). The machine set up was adjusted to deliver (1 mg) bolus and the lockout interval was 10 minutes.

Data for assessments

Heart Rate HR (beats/min) and Mean Arterial Blood Pressure (MAP)

Depth of anesthesia (BIS)

Duration of anesthesia (by minutes): from the time of induction to withdrawal of all anesthetics.

The recovery time (by minutes): from withdrawal of all anesthetics to extubation.

Postoperative pain score by ‘VAS’ (0–100 mm).

Total anesthetic requirements during surgery.

Total postoperative analgesic requirements of morphine (mg) during the 1^st 24 hours.

Statistical analysis

Statistical analysis was done using “SPSS 19 for Windows” software. Data were collected from all patients during and after anesthesia. Descriptive statistics (mean, standard deviation “SD”, and ranges) were calculated. Comparative statistics between the two groups were applied. Unpaired t-test was used to compare the mean values between the two groups. Mann-Whitney-U test was used to compare the difference between the two groups for non parametric variables (e.g. VAS). While, Chi-square test was used to compare the categorical variables between both groups (e.g. surgical diagnosis). Significant result was considered when P value was less than (0.05).

Patient’s characters

Analysis of the results showed that there was no significant difference in patient characters between the two groups (Table 1).

Table 1: Patients' characters.

Anesthetic data

Duration of anesthesia and recovery time: The duration of anesthesia showed no significant difference between the study groups (P>0.05). But the recovery time was significantly shorter in group I (magnesium group) compared to the control group (P<0.05) (Table 2).

Table 2: Anesthetic data (Mean ±SD).

Anesthetic agents consumption: The mean propofol consumption (mg/kg/h) showed a statistically significant decrease (P<0.05) in magnesium group when compared to control group. The intraoperative fentanyl consumption was significantly less (P<0.05) in magnesium group compared with control group. Also the mean rocuronium requirement was significantly less in magnesium group (P<0.05) when compared to control group (Table 2).

Vital signs

Haemodynamics: The pre-operative mean values of HR and MAP (mmHg) were comparable between the two groups (P>0.05). However after induction of anesthesia and thereafter, there was a significant reduction (P<0.05) in HR and MAP mean values in both groups when compared with the preoperative values (Figure 1 and 2).

Figure 1: Mean heart rate values in both groups.

Figure 2: Mean blood pressure values in both groups.

BIS value: There was no significant difference (P>0.05) in the BIS mean values between the study groups starting from the preoperative period and throughout the anesthesia, till after extubation and recovery (Table 3).

Table 3: ‘BIS’ values in both groups (Mean ±SD).

Postoperative pain managements

Postoperative pain assessments by VAS (0-100 mm) showed significantly lower pain scores in magnesium group compared to control group (comparison by Whitney-U test revealed P<0.05) (Figure 3).

Figure 3: Mean visual analog scale values in both group.

As regard the postoperative pain relief, comparison between the two groups (by unpaired t-test) showed that there was a significant reduction (P<0.05) in the total cumulative doses of morphine consumption by PCA during the 1^st 24 hours in magnesium group compared to control group (Table 4).

Table 4: Post-operative morphine consumption by PCA (Mean ± SD).

Hemodynamics

The present study indicates that magnesium sulfate reduced both the HR/min and mean arterial blood pressure throughout the operative time. This was in agreement with many similar studies. Instead of fentanyl, Ryu et al. [6] used remifentanil with propofol as a part of total intravenous anesthesia in two groups of patients, one received magnesium sulfate and the other group received saline. Results showed that the mean MAP and HR were significantly reduced in magnesium group. While, Choi et al. [3] has maintained the hemodynamic parameters at the base line values by changing the propofol infusion rate when the MAP and HR changed and he concluded that the magnesium group required less propofol infusion than the other group. Also these results are in accordance with the results of Telci et al. [7] who adjusted the dose of the remifentanil and propofol according to the hemodynamic changes. Also, it has shown that magnesium decreased the systemic vascular resistance and attenuates the response to laryngoscopy and tracheal intubation [5].

Anesthetic managements

In anesthesia practice, the increases of blood pressure and heart rate are interpreted as the onset of pain and light anesthesia supposing that the other factors are stabilized [8].

There was a significant reduction in the infusion rates of propofol and fentanyl in magnesium group compared to the control group. It has been shown that, when MgSO₄ is co-administered with propofol, it potentiates the anesthetic effect and NMDA antagonism of propofol. This result suggested that magnesium administration may be a useful adjunct to propofol anesthesia and this was associated with reduced propofol requirements [3,6]. Another mechanism could involve the reduction of catecholamine release through reduced sympathetic outflow and decrease the stress response to surgery [8]. This means that magnesium acts as part of balanced general anesthesia with propofol, fentanyl and mivacurium [9]. These results are in agreement with the result of Telci et al. [7] who has shown that the administration of magnesium led to significant reduction in the requirements for anesthetic drugs during total intravenous anesthesia (TIVA) with propofol, remifentanil and vecuronium. In another study, a bolus of 4 gm magnesium resulted in a rapid but transient decrease in arterial blood pressure in hypertensive patients, whereas normotensive patients did not have any significant change in blood pressure [3]. Moreover, Tramer et al. [10] has shown that patients treated with magnesium did not show any significant hemodynamic difference compared with control patients in the intra-operative and post-operative period.

In the present study, I.V magnesium significantly reduced rocuronium consumption than the control group. This is in accordance with the similar studies that demonstrated significant reductions in vecuronium [7] or mivacurium [11] consumptions during TIVA with continuous magnesium administration.

The effect of vecuronium consumption is not surprising, as the effects of magnesium ions at the neuromuscular junction are well known [7]. The effects of magnesium on at the neuromuscular junction can be explained by the decreased release of acetylcholine at the motor nerve terminal, diminished depolarizing action of acetylcholine, and depressed excitability of the muscle fiber membrane, with the first effect being the most important [12]. Magnesium act competitively in blocking the entry of calcium in presynaptic endings. Presynaptic release of acetylcholine and its effects on the postsynaptic muscle receptors were reduced by magnesium [12].

Also, the duration of action of rocuronium was longer in the magnesium group than the control group and less frequent doses were needed. This prolonged action of the muscle relaxant was reported also in the presence of clindamycin and magnesium [13]. An interaction between magnesium sulfate and the none-depolarizing neuromuscular blocking agents (NMBAs) has been documented for many years. This was also observed in patients undergoing cardiac surgery, where administration of magnesium sulfate results in a (30–35 min) prolongation of the neuromuscular blockade induced with intubating and maintenance doses of cisatracurium [14].

In an attempt to speed up the onset of action of the NMBAs, magnesium has been given before pancuronium in one study [15], or before vecuronium and rocuronium in another study, in these settings the onset times were faster in the presence of magnesium [16].

The recovery time from anesthesia was significantly shorter in magnesium group compared to the control group. This was mainly attributed to the lower anesthetic consumptions in the magnesium group compared to the control group. This rapid recovery also reported by other studies in patients who received magnesium sulfate [15,16]. On the other hand Ray M et al. [9] showed that recovery time was significantly prolonged in patients receiving MgSO₄ in comparison to other two groups that received clonidine or saline. They attributed the delay in recovery may be due to CNS depressant effect of MgSO₄.

Post operative analgesia

Magnesium is a non-competitive (NMDA) receptor antagonist with antinociceptive effects. Magnesium sulfate has been previously investigated as a possible adjuvant for intra- and postoperative analgesia. The majority of these studies suggest that perioperative magnesium sulfate reduces anesthetic requirements and improves postoperative analgesia [6].

The present study showed a significant reduction in the total amount of morphine consumption by PCA used for postoperative pain relief as well as the postoperative pain scores in magnesium group compared to the control group. This is in agreement with other studies that showed perioperative magnesium sulfate was associated with smaller analgesic requirement, less discomfort and a better quality of sleep in the postoperative period [10]. While Ryu et al. [6] has shown that postoperative pain scores, cumulative analgesic consumption of morphine, and shivering incidents were significantly lower after intraoperative magnesium infusion. Other study has reported also that pre-operative administration of intravenous magnesium reduced the intra and post-operative analgesic requirements in patients undergoing orthopedic knee surgery or elective abdominal hysterectomy [5]. Also, magnesium could be adjuvant to peri-operative analgesics by lowering the fentanyl requirement [2,17].

The uses of magnesium are not limited to the intra operative infusion only, but in the intensive care unit, magnesium sulfate infusion was associated with decreased sufentanil requirements. While Levaux et al. [18] has used magnesium sulfate as an adjuvant for postoperative analgesia after major lumbar surgery and they observed that the postoperative opioid consumption and pain scores were lower in the magnesium group than the control group. Also, Apan et al. [19] showed that postoperative magnesium sulfate infusion reduces analgesic requirements and prolongs the time to first analgesic request in patients undergoing spinal surgery under spinal anesthesia. Moreover magnesium sulfate administered before induction of anesthesia increases minimum alveolar anesthetic concentration of sevoflurane and reduces cardiovascular responses to intubation [20]. Therefore, it may be worthwhile use magnesium sulfate supplementation to intraoperative anesthetics and postoperative analgesia, since this molecule is inexpensive, relatively harmless, and the biological basis for its potential antinociceptive effect is promising [21].

First, we used only one regimen of magnesium infusions, while clinical studies showed that magnesium causes a dose-dependent negative inotropic effect [22]. Also, in another study, magnesium 40 mg/kg bolus and 10 mg/kg/h infusion regimen seems to fulfill clinical expectations of reducing the requirement for propofol and atracurium intraoperatively, and morphine after operation [23]. Second, the infusion was limited to intra operative period only. While some studies used magnesium infusion postoperatively after spinal anesthesia and showed a significant sedative effect with a reduction of the analgesic consumptions [19]. Third, we didn’t measure the serum level of magnesium and assess the correlations between the magnesium level versus the total anesthetic and analgesic requirements. Lastly, we didn’t evaluate the cost/effective analysis of this cheap medications compared to anesthetic medications. Schulz-Stübner et al. [11] showed that a 2-h anesthetic without magnesium would cost 21–35% more than in magnesium group.

From the previously mentioned data, we can conclude that magnesium sulfate is a safe and cost-effective supplement to a general anesthetic regimen with propofol, fentanyl and rocuronium as it reduces the total anesthetic requirements, post-operative pain score and post-operative analgesic requirements.

The author would like to acknowledge Dr. Salah N. Eltallawy, Associate Professor of Anesthesia and Dr. Abdulaziz E. Ahmad, Registrar of Anesthesia, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia for their help throughout this study. No conflict of interest nor fund had been reported by them.